Navigation Links
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Date:2/11/2008

zation of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I and Phase II combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene's preclinical programs include: MGCD290 an HDAC inhibitor in combination with azoles for fungal infections and a sirtuins program for cancer. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at http://www.methylgene.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements relating to MGCD0103, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include, but are not limited to, the potential failure of MGCD0103, to demonstrate safety and efficacy in clinical and non-clinical testing; the ability to complete regulatory submissions and gain regulatory approvals in a timely manner; the ability to initiate and complete trials at the referenced times; the impact of competition from other products under development by Pharmion's competitors; the uncertainty of the regulatory environment and changes in the health policies of various countries; acceptance and demand for new pharmaceutical pr
'/>"/>

SOURCE Pharmion Corporation; MethylGene Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
2. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
5. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
6. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
7. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
8. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  BioScrip ® , Inc. (NASDAQ: BIOS ) ... Executive Officer, will present at the Bank of America Merrill Lynch ... , Date: , , , Wednesday, December 3, 2014 , ... , , , Location: , , , Boca Raton Resort ... Inc. BioScrip, Inc. is a leading national ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... Pharmaceuticals, Inc., a privately held drug development company, is ... as Executive Chairman of the Board of Directors. ... important milestone for Tigris Pharmaceuticals, future," said Edmundo Muniz, ... brings to Tigris extraordinary ability and pharmaceutical industry experience ...
... Sept. 28 Sunridge International (OTC Bulletin Board: ... glaucoma and ocular hypertension will be introduced in October ... Presentations have been planned by its Indian ... October 1 – 14.  The company,s Pneumatic Trabeculoplasty (PNT), ...
Cached Medicine Technology:Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board 2Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board 3Sunridge to Introduce Their PNT Treatment for Glaucoma to Medical Personnel in India 2
(Date:11/26/2014)... The family foundation of Best Buy founder, Richard ... Foundation (Meso Foundation), half of which will be specifically ... Program . The focus area of the Richard M. ... organizations that can generate transformational results in education, human ... and chairman emeritus of Best Buy Co., Inc., the ...
(Date:11/26/2014)... Arlington, VA (PRWEB) November 26, 2014 ... Ushma Suvarnakar as the Association’s new director of ... directing the Association’s annual meeting, special events and ... Ushma Suvarnakar to this post,” said AAA Executive ... contagious level of enthusiasm and energy. She was ...
(Date:11/26/2014)... For its December issue , Atlantic Information ... Blue Cross and Blue Shield Plans* interviewed officials at ... the two Blues plans are implementing in order to ... apnea, ranging from brick-and-mortar retail stores to patient data ... rates of a variety of serious disorders, including hypertension, ...
(Date:11/26/2014)... GI for Life announced today, that they ... of their popular nutritional supplements: ColoVite Colon Health ... Discounts of 40% will be offered for a limited ... ColoVite supplement is a scientifically formulated vitamin supplement developed ... easy-to-take colon vitamin with ALL the nutrients associated with ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Anthropologists ... effectiveness in containing and stopping Ebola, improve international ... in healthcare systems in West Africa. , ... to Stop Ebola: Anthropologists Offer Insights,” will be ... the American Anthropological Association (AAA), Fri., Dec. 5, ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3
... developed a fertility predictor test, which enables women to ... or decreasing. This will be particularly useful to women ... best age for child bearing is// reported to be ... of the Sheffield University. But the pressure of modern ...
... School is exploring the beneficial properties of Lactic acid ... is used for fermentation of curd and yogurt, used ... also as applications in saving fish culture system from ... inhibit the binding of HIV virus into the mucous ...
... over safety with regard to the hormone replacement therapy (HRT), another ... from diseases related to the heart. //The risk of a coronary ... who start with the HRT at an younger age, when in ... ,There are no cardiovascular benefits to be seen in the case ...
... Washington University School of Medicine identify yet another reason to ... been found to play a critical role in the development// ... diet have been found to have a low bone mass. ... 18 individuals aged between 33 and 85 years, under a ...
... themselves to come out of the financial crisis they ... British Health secretary as welcomed better financial management ... cutting unnecessary fund wastage. ,The health ... the NHS hospitals will be followed and finance management ...
... gave the all clear to 21 women who had breast ... chances of fighting and surviving the disease//. ,It ... years after she was given a clean chit by the ... Manchester. The said radiologist worked at Trafford General and the ...
Cached Medicine News:Health News:Raw Vegan Diet Promises Lightweight, Healthy Bones 2
The 96 PW is an intelligent full microplate washer with a 96 needle wash head washing all wells simultaneously. This instrument gives high throughput and outstanding washing efficiency....
Stat Fax 2600 is fully automatic microplate washer....
... 1575 immunowash microplate washer ... needle position to perform ... maximize wash efficiency. This ... choice of wash that ...
... LMW Automated Microplate ... choice for any laboratory. ... sensor allows a precise ... residual volume, digitally controlled ...
Medicine Products: